130 related articles for article (PubMed ID: 20703211)
1. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
[TBL] [Abstract][Full Text] [Related]
2. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R
Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971
[TBL] [Abstract][Full Text] [Related]
5. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
7. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
8. De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients.
Novoa PA; Grinyó JM; Ramos FJ; Errasti P; Franco A; Aldana G; Pefaur J; Marti-Cuadros AM; Otero AB; Saval N; Oppenheimer F
Transplant Proc; 2011 Nov; 43(9):3331-9. PubMed ID: 22099791
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
12. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
[TBL] [Abstract][Full Text] [Related]
13. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
[TBL] [Abstract][Full Text] [Related]
15. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy.
Sánchez-Brotons JA; Sobrino-Márquez JM; Lage-Gallé E; Romero-Rodriguez N; Guisado A; Jiménez-Díaz J; Benezet-Mazuecos J; Arizón-Muñoz JM; Mogollón MV; Martínez A
Transplant Proc; 2008 Nov; 40(9):3046-8. PubMed ID: 19010188
[TBL] [Abstract][Full Text] [Related]
16. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
[No Abstract] [Full Text] [Related]
18. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[TBL] [Abstract][Full Text] [Related]
20. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
